TrialInvestigational new drugs2015

A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study.

Norisuke Nakayama et al.PubMed ↗Publisher ↗

No numbers read from the abstract.